$1.07 Billion is the total value of Consonance Capital Management LP's 38 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TCRR | Sell | TCR2 THERAPEUTICS INC | $71,268,000 | +132.3% | 584,885 | -61.3% | 6.66% | +78.1% |
| ATRA | Sell | ATARA BIOTHERAPEUTICS INC | $69,348,000 | +14.2% | 3,532,738 | -24.6% | 6.48% | -12.4% |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $65,410,000 | -13.1% | 4,480,163 | -15.5% | 6.11% | -33.4% |
| MGNX | Sell | MACROGENICS INC | $52,574,000 | -44.3% | 2,299,829 | -38.6% | 4.91% | -57.3% |
| MRSN | Sell | MERSANA THERAPEUTICS INC | $37,299,000 | -42.2% | 1,401,703 | -59.6% | 3.48% | -55.7% |
| KDMN | Sell | KADMON HLDGS INC | $30,501,000 | -44.5% | 7,349,621 | -47.5% | 2.85% | -57.4% |
| ISEE | Sell | IVERIC BIO INC | $16,404,000 | -24.4% | 2,373,924 | -38.3% | 1.53% | -42.0% |
| ATNM | Sell | ACTINIUM PHARMACEUTICALS INC | $690,000 | -91.0% | 88,428 | -88.9% | 0.06% | -93.2% |
| OMER | Exit | OMEROS CORP | $0 | – | -484,042 | -100.0% | -0.60% | – |
| SLNO | Exit | SOLENO THERAPEUTICS INC | $0 | – | -3,040,000 | -100.0% | -0.93% | – |
| AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -3,236,335 | -100.0% | -1.82% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -1,736,012 | -100.0% | -2.31% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -2,005,218 | -100.0% | -3.62% | – |
| LMNL | Exit | LIMINAL BIOSCIENCES INC | $0 | – | -3,084,627 | -100.0% | -4.18% | – |
| APRE | Exit | APREA THERAPEUTICS INC | $0 | – | -1,459,411 | -100.0% | -4.28% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -2,374,392 | -100.0% | -4.43% | – |
| CGEN | Exit | COMPUGEN LTDord | $0 | – | -2,637,421 | -100.0% | -5.22% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -7,994,904 | -100.0% | -5.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.